iShares Biotechnology ETF (NASDAQ:IBB) Shares Sold by Westwood Wealth Management

Westwood Wealth Management lessened its holdings in shares of iShares Biotechnology ETF (NASDAQ:IBB) by 1.2% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 12,325 shares of the financial services provider’s stock after selling 150 shares during the quarter. iShares Biotechnology ETF accounts for 0.6% of Westwood Wealth Management’s portfolio, making the stock its 20th largest position. Westwood Wealth Management’s holdings in iShares Biotechnology ETF were worth $1,692,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in IBB. BNP Paribas Financial Markets boosted its holdings in iShares Biotechnology ETF by 25.7% in the first quarter. BNP Paribas Financial Markets now owns 2,055,373 shares of the financial services provider’s stock worth $282,038,000 after purchasing an additional 420,053 shares during the period. Global Assets Advisory LLC bought a new stake in shares of iShares Biotechnology ETF during the 1st quarter valued at about $66,059,000. Raymond James Financial Services Advisors Inc. grew its position in shares of iShares Biotechnology ETF by 24.6% during the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 217,047 shares of the financial services provider’s stock valued at $29,792,000 after buying an additional 42,822 shares during the last quarter. Commonwealth Equity Services LLC raised its stake in iShares Biotechnology ETF by 5.3% during the first quarter. Commonwealth Equity Services LLC now owns 198,709 shares of the financial services provider’s stock worth $27,267,000 after acquiring an additional 10,033 shares during the period. Finally, Raymond James & Associates lifted its holdings in iShares Biotechnology ETF by 4.4% in the second quarter. Raymond James & Associates now owns 189,766 shares of the financial services provider’s stock worth $26,047,000 after acquiring an additional 7,931 shares during the last quarter. 62.45% of the stock is currently owned by hedge funds and other institutional investors.

iShares Biotechnology ETF Stock Down 1.6 %

NASDAQ:IBB opened at $145.58 on Tuesday. The stock has a 50 day moving average of $145.81 and a 200-day moving average of $138.68. iShares Biotechnology ETF has a 52 week low of $111.83 and a 52 week high of $150.57.

iShares Biotechnology ETF Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.